JP2022527405A5 - - Google Patents

Info

Publication number
JP2022527405A5
JP2022527405A5 JP2021560206A JP2021560206A JP2022527405A5 JP 2022527405 A5 JP2022527405 A5 JP 2022527405A5 JP 2021560206 A JP2021560206 A JP 2021560206A JP 2021560206 A JP2021560206 A JP 2021560206A JP 2022527405 A5 JP2022527405 A5 JP 2022527405A5
Authority
JP
Japan
Prior art keywords
length
tgcd3
partial
cells
full
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021560206A
Other languages
English (en)
Japanese (ja)
Other versions
JP7783746B2 (ja
JP2022527405A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027327 external-priority patent/WO2020210398A1/en
Publication of JP2022527405A publication Critical patent/JP2022527405A/ja
Publication of JP2022527405A5 publication Critical patent/JP2022527405A5/ja
Application granted granted Critical
Publication of JP7783746B2 publication Critical patent/JP7783746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021560206A 2019-04-11 2020-04-08 操作されたiPSCおよび免疫エフェクター細胞におけるCD3の再構成 Active JP7783746B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832622P 2019-04-11 2019-04-11
US62/832,622 2019-04-11
PCT/US2020/027327 WO2020210398A1 (en) 2019-04-11 2020-04-08 CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS

Publications (3)

Publication Number Publication Date
JP2022527405A JP2022527405A (ja) 2022-06-01
JP2022527405A5 true JP2022527405A5 (cg-RX-API-DMAC10.html) 2023-04-18
JP7783746B2 JP7783746B2 (ja) 2025-12-10

Family

ID=72750569

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021560206A Active JP7783746B2 (ja) 2019-04-11 2020-04-08 操作されたiPSCおよび免疫エフェクター細胞におけるCD3の再構成

Country Status (12)

Country Link
US (1) US20220184142A1 (cg-RX-API-DMAC10.html)
EP (1) EP3953453A4 (cg-RX-API-DMAC10.html)
JP (1) JP7783746B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210139472A (cg-RX-API-DMAC10.html)
CN (1) CN113906133A (cg-RX-API-DMAC10.html)
AU (1) AU2020271523B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021019772A2 (cg-RX-API-DMAC10.html)
CA (1) CA3135224A1 (cg-RX-API-DMAC10.html)
IL (1) IL286858A (cg-RX-API-DMAC10.html)
MX (1) MX2021012054A (cg-RX-API-DMAC10.html)
SG (1) SG11202110601UA (cg-RX-API-DMAC10.html)
WO (1) WO2020210398A1 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
EP4578507A3 (en) 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
KR20230040337A (ko) 2020-06-19 2023-03-22 페이트 세러퓨틱스, 인코포레이티드 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
CN114525259B (zh) * 2020-11-03 2025-02-14 南京北恒生物科技有限公司 靶向cd7的嵌合抗原受体及其用途
WO2022098914A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
WO2022099297A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Multiplexed engineered ipsc and immune effector cells targeting solid tumors
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
IL303269A (en) 2020-12-03 2023-07-01 Century Therapeutics Inc Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202241935A (zh) 2020-12-18 2022-11-01 美商世紀治療股份有限公司 具有可調適受體專一性之嵌合抗原受體系統
CN117083375A (zh) * 2021-01-29 2023-11-17 艾洛基治疗公司 敲低或敲除TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP和RFXANK中的一个或多个以减轻同种异体细胞产物的T细胞识别
MX2023008809A (es) 2021-01-29 2023-08-04 Allogene Therapeutics Inc ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS.
CA3209946A1 (en) * 2021-03-05 2022-09-09 Matthew Angel Engineered immune cell therapies
CN113528453B (zh) * 2021-07-07 2023-05-12 金宇保灵生物药品有限公司 一种永生化猪巨噬细胞株及其构建方法和应用
GB202110363D0 (en) * 2021-07-19 2021-09-01 Celyad S A NKG2D CAR cells expressing IL-18 for adoptive cell therapy
EP4504221A4 (en) * 2022-03-22 2026-02-25 Celyntra Therapeutics Sa Compositions and methods for generating cells with reduced immunogenicity
WO2023233342A2 (en) * 2022-06-01 2023-12-07 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2024047561A1 (en) * 2022-09-02 2024-03-07 Janssen Biotech, Inc. Biomaterials and processes for immune synapse modulation of hypoimmunogenicity
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
WO2025076485A1 (en) * 2023-10-05 2025-04-10 Mink Therapeutics, Inc. Novel invariant natural killer t cells and t cell engager compositions and methods of use thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
WO2026019829A1 (en) * 2024-07-15 2026-01-22 A2 Biotherapeutics, Inc. Compositions and methods for stimulating t cells used in cell therapy with a bispecific bridging molecule

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3789487A1 (en) * 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
KR20160145186A (ko) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
EP3166647A4 (en) * 2014-07-09 2018-02-14 The Regents of the University of California Engineered invariant natural killer t (inkt) cells and methods of making and using thereof
GB201506642D0 (en) * 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
ES2803728T3 (es) * 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
US12642852B1 (en) 2015-11-04 2026-06-02 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
KR102614675B1 (ko) 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
US20200087681A1 (en) * 2016-12-21 2020-03-19 Ucl Business Plc Therapeutic cells
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
CA3093449A1 (en) * 2018-03-09 2019-09-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins

Similar Documents

Publication Publication Date Title
JP2021519061A5 (cg-RX-API-DMAC10.html)
JP2022541441A5 (cg-RX-API-DMAC10.html)
JP2021505131A5 (cg-RX-API-DMAC10.html)
JP2022548943A5 (cg-RX-API-DMAC10.html)
JP2022550899A5 (cg-RX-API-DMAC10.html)
JP2022510207A5 (cg-RX-API-DMAC10.html)
JP2023505206A5 (cg-RX-API-DMAC10.html)
JP2023548467A5 (cg-RX-API-DMAC10.html)
US20250270279A1 (en) Polypeptide useful in adoptive cell therapy
JP2022552314A5 (cg-RX-API-DMAC10.html)
JP2023549098A5 (cg-RX-API-DMAC10.html)
Lipowska-Bhalla et al. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges
JP2023530704A5 (cg-RX-API-DMAC10.html)
JP2023548829A5 (cg-RX-API-DMAC10.html)
Dotti et al. Fifteen years of gene therapy based on chimeric antigen receptors:“are we nearly there yet?”
JP7623020B2 (ja) 同種異系移植のための操作された免疫細胞
JP7783746B2 (ja) 操作されたiPSCおよび免疫エフェクター細胞におけるCD3の再構成
JP2023118962A (ja) 非hla制限t細胞受容体およびその使用
JP2024518011A (ja) 多様な免疫細胞のための単鎖および多鎖合成抗原受容体
Maher Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells
US11299552B2 (en) Eliminating MHC restriction from the T cell receptor as a strategy for immunotherapy
JP2022531222A5 (cg-RX-API-DMAC10.html)
JPWO2020045610A1 (ja) Car発現t細胞及びcar発現ベクター
JP2021513347A5 (cg-RX-API-DMAC10.html)
JP2023545992A5 (cg-RX-API-DMAC10.html)